David Hirsch is the founder of Alpha9 Theranostics. Alpha9 Theranostics has raised $86M in total funding. Latest round: Series B. Backed by Longitude Capital.
David Hirsch is the Chief Executive Officer of Alpha-9 Theranostics, a clinical-stage biotech company focused on developing next-generation radiopharmaceuticals for cancer treatment. He co-founded the company with three University of British Columbia researchers after previously serving as a venture partner at Longitude Capital.
Full founder directory · Investor directory · Company funding database · Fundraising library